دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Digital therapeutics for remote symptom monitoring and management in cancer care: the current and future state
E. Basch
doi : 10.1016/j.annonc.2023.06.003
Volume 34, Issue 8, August 2023, Pages 635-637
Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy
doi : 10.1016/j.annonc.2023.05.006
Volume 34, Issue 8, August 2023, Pages 638-644
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
P. Tarantino 1,2,3 , G. Viale4 , M. F. Press5 , X. Hu 6 , F. Penault-Llorca 7 , A. Bardia2,8 , A. Batistatou 9 , H. J. Burstein1,2 , L. A. Carey10 , J. Cortes11,12 , C. Denkert13 , V. Diéras 14 , W. Jacot 15 , A. K. Koutras16 , A. Lebeau17 , S. Loibl 18,19 , S. Modi20 , M. F. Mosele 21 , E. Provenzano 22 , G. Pruneri3,23 , J. S. Reis-Filho 24 , F. Rojo 25 , R. Salgado26,27 , P. Schmid 28 , S. J. Schnitt 2,29 , S. M. Tolaney 1,2 , D. Trapani 3,30 , A. Vincent-Salomon 31 , A. C. Wolff 32 , G. Pentheroudakis33 , F. André34 & G. Curigliano
doi : 10.1016/j.annonc.2023.05.008
Volume 34, Issue 8, August 2023, Pages 645-659
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial
N. Harbeck 1,2* , P. A. Fasching 3 , R. Wuerstlein1,2 , T. Degenhardt 1,4 , D. Lüftner 5,6 , R. E. Kates 2 , J. Schumacher 7 , P. R?th 7 , O. Hoffmann 8 , R. Lorenz 9 , T. Decker 10 , M. Reinisch11,12 , T. G?hler13 , P. Staib 14 , O. Gluz 2 , T. Schink?the15,16 & M. Schmidt17 , on behalf of the AGO-B WSG PreCycle investigators (see Appendix 1)
doi : 10.1016/j.annonc.2023.05.003
Volume 34, Issue 8, August 2023, Pages 660-669
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study
M. Oliveira 1,2 , C. Falato 1,3,4 , J. M. Cejalvo1,5 , M. Margel? Vila 1,6 , P. Tolosa 1,7 , F. J. Salvador-Bofill 1,8 , J. Cruz 1,9 , M. Arumi1,2 , A. M. Luna 1,10 , J. A. Guerra1,11 , M. Vidal 1,3,12 , O. Mart?nez-S?ez 1,3,12 , L. Paré 1 , B. Gonz?lez-Farré1,13 , E. Sanfeliu1,13 , E. Ciruelos 1,7 , M. Espinosa-Bravo1,14 , S. Pernas1,15 , Y. Izarzugaza1,16 , S. Esker 17 , P.-D. Fan 17 , P. Parul 17 , A. Santhanagopal17 , D. Sellami 17 , G. Villacampa 1 , J. M. Ferrero-Cafiero1 , T. Pascual1,3,12 & A. Prat
doi : 10.1016/j.annonc.2023.05.004
Volume 34, Issue 8, August 2023, Pages 670-680
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
I. Ray-Coquard1,2* , A. Leary2,3 , S. Pignata4,5 , C. Cropet2,6 , A. Gonz?lez-Mart?n7,8 , C. Marth9,10 , S. Nagao11,12 , I. Vergote13,14 , N. Colombo15,16 , J. M?enp??17,18 , F. Selle2,19 , J. Sehouli20,21 , D. Lorusso5,22 , E. M. Guerra Alia8,23 , G. Bogner10,24 , H. Yoshida12,25 , C. Lefeuvre-Plesse2,26 , P. Buderath21,27 , A. M. Mosconi5,28 , A. Lortholary2,29 , A. Burges21,30 , J. Medioni2,31 , A. El-Balat21,32,33 , M. Rodrigues2,34 , T.-W. Park-Simon21,35 , C. Dubot2,36 , D. Denschlag21,37 , B. You2,38 , E. Pujade-Lauraine39 & P. Harter21,40 , for the PAOLA-1/ENGOT-ov25 investigatorsy
doi : 10.1016/j.annonc.2023.05.005
Volume 34, Issue 8, August 2023, Pages 681-692
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications
M. Burotto 1, Z. Zvirbule 2 , A. Mochalova 3 , Y. Runglodvatana 4 , L. Herraez-Baranda5 , S. N. Liu6 , P. Chan 6 , E. Shearer-Kang 7 , X. Liu 8 , N. Tosti9 , J. A. Zanghi10 , B. Leutgeb9y & E. Felip 11,12
doi : 10.1016/j.annonc.2023.05.009
Volume 34, Issue 8, August 2023, Pages 693-702
Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability
T. Ratovomanana 1y, R. Nicolle 2,3y, R. Cohen 1,3,4 , A. Diehl1 , A. Siret1 , Q. Letourneur 1 , O. Buhard1 , A. Perrier 1,5 , E. Guillerm1,5 , F. Coulet 1,5 , P. Cervera 1 , P. Benusiglio1,5 , K. Labrèche6 , R. Colle 1,3,4 , A. Collura1 , E. Despras 1 , P. Le Rouzic1 , F. Renaud 1 , J. Cros 7 , A. Alentorn 8 , M. Touat8 , M. Ayadi9 , P. Bourgoin1,10 , C. Prunier 11 , C. Tournigand 12 , C. de la Fouchardière13 , D. Tougeron 14 , V. Jonchère 1 , J. Bennouna15 , A. de Reynies 16 , J.-F. Fléjou 1,10 , M. Svrcek 1,10 , T. André1,3,4 & A. Duval
doi : 10.1016/j.annonc.2023.05.010
Volume 34, Issue 8, August 2023, Pages 703-713
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer
A.J. Rosenberg1,2* , C.-Y. Liao 1,2 , T. Karrison3 , J.A. de Souza4 , F.P. Worden5 , B. Libao 1 , M.K. Krzyzanowska6 , D.N. Hayes 7 , E. Winquist8 , V. Saloura9 , K. Prescott10 , V.M. Villaflor 11 , T.Y. Seiwert 12 , R.B. Schechter1 , W.M. Stadler 1,2 , E.E.W. Cohen13 & E.E. Vokes
doi : 10.1016/j.annonc.2023.05.002
Volume 34, Issue 8, August 2023, Pages 714-722
Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer
T. Olivier 1 * & V. Prasad
doi : 10.1016/j.annonc.2023.06.005
Volume 34, Issue 8, August 2023, Pages 723-724
Corrigendum to “Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level�: [Annals of Oncology 34 (2023) 327-332]
L. Bazhenova
doi : 10.1016/j.annonc.2023.05.007
Volume 34, Issue 8, August 2023, Pages 725-726
Erratum to “P-309 In vitro drug screening of patient-specific tumoroids to predict chemotherapeutic treatment response in pancreatic ductal adenocarcinoma: An interim analysis�: [Annals of Oncology 33 suppl. 4 (2022) S355]
C. Nitschke1* , C. Phan2 , L. Konczalla1 , M. Goetz1 , M. Sinn 3 , O. Thastrup4 , J. Izbicki1 , F. Uzunoglu1 & T. Sturmheit
doi : 10.1016/j.annonc.2022.12.001
Volume 34, Issue 8, August 2023, Pages 727-728
